DALLAS, Feb. 26 /PRNewswire-FirstCall/ -- HemoBioTech announced today that Dr. Arthur P. Bollon, Chairman and CEO of HemoBioTech will make a presentation at the MedTech Insight conference “Investment in Innovation (In3) West: a Preview of Early-Stage Medical Technology Companies” in Irvine, California on February 27, 2007. Dr. Bollon will present an overview of HemoBioTech and its lead product HemoTech(TM).
The conference features several emerging medical technology companies and will be attended by investment bankers, venture capitalists, analysts and executives from biotechnology and pharmaceutical companies.
About HemoBioTech, Inc.
HemoBioTech is engaged in the development of HemoTech(TM), a novel human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. HemoTech(TM) is composed of bovine hemoglobin which is chemically modified with ATP, adenosine and GSH. HemoTech(TM) not only can carry oxygen in the blood, but can also induce erythropoiesis (red blood cell production). The Company believes that HemoTech(TM), due to its novel structure, may possess properties that diminish the intrinsic toxicities which have plagued other attempts at developing blood substitutes, based upon pre- clinical and initial human clinical trials undertaken outside the U.S. by prior holders of this technology. HemoTech(TM) is being subjected to further studies and testing to confirm and possibly expand on these results. HemoTech(TM) is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, as well as for other conditions. Corporate headquarters are located at 5001 Spring Valley Road, Suite 1040- West, Dallas, Texas 75244. For further information contact Dr. Arthur Bollon at 972-455-8950 or abollon@hemobiotech.com . The Company website is http://www.hemobiotech.com .
Safe Harbor Statement
Except for historical information, the matters discussed in this news release may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre- clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTech’s Annual Report on Form 10-KSB for the year ended December 31, 2005, as amended, and HemoBioTech’s other reports filed with the Securities and Exchange Commission.
HemoBioTech, Inc.
CONTACT: Dr. Arthur Bollon of HemoBioTech, Inc., +1-972-455-8950, orabollon@hemobiotech.com
Web site: http://www.hemobiotech.com/
